Q-omics provides the consensus-scored UBE2N profile across patient tissues and cancer cell-line models. UBE2N expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UBE2N is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, UBE2N RNA expression shows 19,706 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, BLCA, and ACC as cancer lineages where UBE2N shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2N — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2N survival associations across molecular data types. UBE2N RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2N RNA expression–survival associations across cancer types. High UBE2N expression shows unfavorable associations in LIHC, UVM, HNSC, MESO, ACC and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UBE2N RNA expression.
This table summarizes UBE2N tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for UBE2N. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2N shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, LIHC, HNSC and BRCA. The BLCA box plot shows higher UBE2N RNA expression in tumor versus normal tissue (log2 FC = +0.432, t-test p < 0.001).
This table shows molecular features associated with UBE2N in patient tissues and cancer cell lines. In patient samples, UBE2N shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2N RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
